Larissa B. Thackray

TL;DR: An analysis identifies human monoclonal antibodies that potently neutralize wild-type SARS-CoV-2 and protect animals from disease, including two that synergize in a cocktail, suggesting that these could be candidates for use as therapeutic agents for the treatment of COVID-19 in humans.

TL;DR: The capacity of MNV-1 to replicate in a STAT-1-regulated fashion and the unexpected tropism of a norovirus for cells of the hematopoietic lineage provide important insights into Norovirus biology.

TL;DR: The data suggest that the large S glycoprotein of SARS-CoV may use both ACE2 and CD209L in virus infection and pathogenesis, and several other enveloped viruses including Ebola and Sindbis also useCD209L as a portal of entry.

TL;DR: This chapter discusses human noroviruses, which are the major cause of nonbacterial, epidemic gastroenteritis worldwide and cause significant numbers of endemic cases, as well as investigating the mechanisms behind their spread.

TL;DR: Transduced replication-defective adenoviruses encoding human ACE2 via intranasal administration into BALB/c mice and established receptor expression in lung tissues and passive transfer of a neutralizing monoclonal antibody reduced viral burden in the lung and mitigated inflammation and weight loss.